News | September 12, 2024
AGC and Medinet sign agreement for cell therapy CDMO business
A new initiative to contribute to enhancing drug discovery capabilities in the field of gene and cell therapy in Japan
A new initiative to contribute to enhancing drug discovery capabilities in the field of gene and cell therapy in Japan
ALS patients experience neuroinflammation and rapid neurodegeneration
The trial met its primary and secondary endpoints demonstrating that administration of a 3-dose regimen of GARDASIL 9
TROPION-Lung01, evaluating AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan versus chemotherapy, previously met the dual primary endpoint of progression-free survival in the overall trial population
Agreement further expands Aptar Pharma’s leading respiratory portfolio
The patient has been isolated in a designated hospital and is currently stable
Objective response rate of 54.8% seen with Daiichi Sankyo and Merck’s ifinatamab deruxtecan at 12 mg/kg dose in pretreated patients
The company has entered into a long-term lease and operations and management agreement with Sree Chand Specialty Hospital, situated in Kannur
The companies will combine Nanoform’s Biologics platform with the Celanese VitalDose Drug Delivery platform to further optimize controlled release of biologics
Multi-year collaboration focuses on development of biodegradable antimicrobial peptides with broad application possibilities in the areas of skin care and healthcare
Subscribe To Our Newsletter & Stay Updated
